---
title: Retrospective Study of Brachytherapy
nct_id: NCT05242861
overall_status: RECRUITING
sponsor: Zhejiang Cancer Hospital
study_type: OBSERVATIONAL
primary_condition: Brachytherapy
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05242861.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05242861"
ct_last_update_post_date: 2022-02-16
last_seen_at: "2026-05-12T06:17:12.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Retrospective Study of Brachytherapy

**Official Title:** A Retrospective Study of Brachytherapy in Gynecological Cancers

**NCT ID:** [NCT05242861](https://clinicaltrials.gov/study/NCT05242861)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 300
- **Lead Sponsor:** Zhejiang Cancer Hospital
- **Conditions:** Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer, Vaginal Cancer, Ovarian Neoplasms, Gynecologic Neoplasm
- **Start Date:** 2022-02-20
- **Completion Date:** 2027-12-31
- **CT.gov Last Update:** 2022-02-16

## Brief Summary

Brachytherapy for gynecological cancers will be studied retrospectively.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 - 80 female
* Underwent brachytherapy
* With gynecological cancer

Exclusion Criteria:

* Refusal to enter this trial
```

## Arms

- **Cervix radical BT**
- **Cervix adjuvant BT**
- **Cervix palliative BT**
- **Uterus BT**
- **Other GO cancer BT**

## Interventions

- **Brachytherapy** (RADIATION) — Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy

## Primary Outcomes

- **Overall survival rate** _(time frame: 5-year)_ — the percentage of participants in the group who survives

## Secondary Outcomes

- **Progression-free survival rate** _(time frame: 5-year)_
- **Side effects** _(time frame: 5-year)_

## Locations (1)

- Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.zhejiang cancer hospital|hangzhou|zhejiang|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05242861.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05242861*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*